Loading stock…

Recordati Industria Chimica e Farmaceutica S.p.A. (REC) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Recordati Industria Chimica e Farmaceutica S.p.A.

RECMarket cap $12BPrice $59.8

Country🇮🇹Italy

SectorHealthcare

IndustryPharmaceuticals

Develops and sells treatment for rare diseases and specialty pharmaceuticals, focusing on drugs so niche that big pharma often ignores them. This Italian company built a global business by dominating overlooked corners of medicine that treat small patient populations profitably.

In Bastion Portfolios?

52W Return+1%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+16%8

Revenue Forecast

Rev CAGR (1y)+2%3

Rev CAGR (3y)+7%5

Rev CAGR (5y)+8%7

Earnings Forecast

EPS Growth Y+1+44%9

EPS Growth Y+2+17%8

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin30%9

Net Income Margin18%8

Free Cash Flow Margin22%8

Debt

Net Debt/EBITDA1.94

Efficiency

ROE25%9

ROA9%8

Earnings Stability55

GEAR+VERY STRONG93

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)156

P/E Ratio (Forward 3y)136

P/BV5.13

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd165

Yield

Free Cash Flow Yield5.5%7

Dividend Yieldna–

Momentum

Short term

1 month return+2%8

3 month return+2%7

YTD return+10%6

Mid term

Price vs 52wHigh99%10

1 year return+1%5

Long term

3 year return+25%4

5 year return+22%5

Risk Shield

Price Risk

Beta0.67

Volatility17%10

Free Cash Flow

Free Cash Flow Margin22%8

Free Cash Flow Yield5.5%7

Quality

ROCE20%9

Earnings Stability55

Net Debt/EBITDA1.94

02Growth

Is it actually growing, and how fast?

RECRecordati Industria Chimica e Farmaceutica S.p.A.

Revenue FY25$3.1B

GROWTH RATING↗

AVERAGE55 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+44%9

EPS growth, FY27E+17%8

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 17%/yr vs revenue 7%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 55% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 7%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

RECRecordati Industria Chimica e Farmaceutica S.p.A.

Total return Current162%

Price return Current111%

MOMENTUM RATING↗

STRONG69 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%8

3-month return+2%7

YTD return+10%6

MID & LONG-TERM▾SCORE

% of 52-week high99%10

1-year return+1%5

3-year return+25%4

5-year return+22%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 1% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+2%) and over three months (+2%).

WATCH

Average long-term results. Multi-year returns are middling (+25% over three years and +22% over five), roughly average for the market.

Returns sit at the market level so far this year (+10%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Recordati Industria. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

RECRecordati Industria Chimica e Farmaceutica S.p.A.

Revenue FY25$3.1B

GROWTH RATING↗

AVERAGE55 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+8%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+44%9

EPS growth, FY27E+17%8

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

The runway holds up: revenue is set to grow 8%/yr over five years.7/10

Earnings are set to grow faster than sales (EPS about 17%/yr vs revenue 7%/yr), so margins should widen.

WATCH

A mid-pack grower, ahead of 55% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 7%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

RECRecordati Industria Chimica e Farmaceutica S.p.A.

Total return Current162%

Price return Current111%

MOMENTUM RATING↗

STRONG69 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%8

3-month return+2%7

YTD return+10%6

MID & LONG-TERM▾SCORE

% of 52-week high99%10

1-year return+1%5

3-year return+25%4

5-year return+22%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 1% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+2%) and over three months (+2%).

WATCH

Average long-term results. Multi-year returns are middling (+25% over three years and +22% over five), roughly average for the market.

Returns sit at the market level so far this year (+10%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Recordati Industria. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community